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Abstract
Netrin-4 is a laminin-related secreted molecule originally found to have roles in neuronal axon migration. Recent stud-
ies have indicated that netrin-4 also participates in the development of nonneural tissues and modulates tumor cell
proliferation and tumor metastasis. Here we have explored the functions and molecular mechanisms of netrin-4 in
glioblastoma multiforme. The suppression of netrin-4 expression in glioblastoma cell lines significantly reduced cell
proliferation and motility and increased serum deprivation–induced apoptosis. Using tandem affinity purification
combined with protein identification by mass spectrometry, we found that integrin β4 interacts with netrin-4 and
that it mediates mitogenic effects as well as AKT and mammalian target of rapamycin phosphorylation induced
by netrin-4. Interestingly, netrin-4 acted as an inhibitor of cell proliferation in integrin β4–silenced glioblastoma cells,
and high concentrations of netrin-4 reduced cell proliferation. The negative effects of netrin-4 on proliferation were
mediated by UNC5B. Analysis of more than 400 primary tumors from The Cancer Genome Atlas repository revealed
that the expression of netrin-4 is significantly downregulated in glioblastoma and that the reduced expression is
linked to poor patient survival time. The expression of integrin β4 is increased in glioblastoma, and it predicts poor
patient survival time. Current results illustrate a novel mechanism for glioma progression, where glioma cells reduce
netrin-4 expression to decrease its inhibitory effects. In parallel, the expression of integrin β4 is upregulated to
sensitize the cells to low concentrations of netrin-4 for maintaining cell proliferation.
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Introduction
Netrins (NTNs) are laminin-related secreted molecules with roles in em-
bryogenesis and tumor development. So far, five mammalian members
have been identified in this family: netrin-1, -3, -4, -G1, and -G2 [1].
Netrin-1 (NTN1) has been defined as a neuronal guidance cue dis-
playing both attractive and repulsive roles for neuronal cells and axons.
Both netrin receptor deleted in colorectal cancer (DCC) and netrin
receptor uncoordinated 5 (UNC5s) are major receptors mediating
the attractive and repulsive effects of NTN1 [1,2]. Similar to the dual
role in axon guidance, the biphasic function of NTN1 appears in the
development of the vasculature, reflected by contrasting results in vari-
ous studies [3–6]. NTN1 can also modulate the development of many
other tissues such as the mammary gland, the pancreas, and the lung
[7–9]. During tumor progression, NTN1 acts as a survival factor for
numerous types of tumor cells during tumor progression through a
“dependence-receptor” mechanism [10].
Another member of the NTN family, netrin-4 (NTN4), is expressed
throughout the central nervous system (CNS) and brings beneficial
effects for the neuronal development [11–13]. Recent studies have
illustrated that NTN4 participates in the development of nonneural tis-
sues by modulating the adhesion, migration, proliferation, and apoptosis
of endothelial cells [5,14–17]. NTN4 can also act as a regulator of tumor
cell proliferation, apoptosis, angiogenesis, and metastasis [15,18,19].
However, the results of the effects of NTN4 have been discordant in
the regulation of tumor progression. NTN4 can also act as an inhibitor
of both tumor growth and angiogenesis with relatively high concen-
trations of NTN4 [16,18,19]. NTN4 has also beneficial effects for
tumor cells by promoting tumor cell proliferation, angiogenesis, and
lymphangiogenesis at relatively low concentrations [5,15,19]. The ex-
pression of NTN4 is upregulated in the effusions or invading edge of
solid tumor compared with corresponding tumor core [20,21], suggest-
ing that NTN4 may have roles in tumor cell migration and invasion.
Several molecules have been identified to interact or form complex
with NTN4, such as neogenin, UNC5B, UNC5D, laminin γ chain,
and integrin α6β1, integrin α3β1, integrin α2β1 [12,16,17,22–24]. How-
ever, the roles of these interactions are still under discussion, and the
biologic functions mediated by these molecules remain largely unclear.
Glioblastoma multiforme (GBM) is the most common malignant
tumor of CNS [25]. NTN4 is strongly expressed by astrocytes [11]
and astrocyte stem cells [12]. White matter–invading glioblastoma cells
express more NTN4 than tumor cores do [20]. However, the func-
tions and molecular mechanisms of NTN4 in glioblastoma need more
elucidation. We have explored here the biologic functions of NTN4 in
glioblastoma cell lines and analyzed the potential underlying molecular
mechanisms for growth modulation.
Materials and Methods
Cell Lines and Reagents
293FT cells (Invitrogen Life Technology, Carlsbad, CA), Astrocytes
(Lonza, Switzerland), U251MG cells (Health Science Research Re-
sources Bank, Osaka, Japan), and U87MG and U373MG (American
Type Culture Collection, Rockville, MD) were cultured according to
the supplier’s instructions. Cell migration and proliferation assays were
performed by using recombinant NTN4 (R&D Systems, Minneapolis,
MN) as modulator.
The following primary antibodies were used: anti-HA.11 from
Covance, Princeton, NJ; anti-NTN4 from R&D Systems; anti-ITGB4
from Sigma-Aldrich, St Louis, MO; anti–phospho-AKT (Ser473),
anti–phospho-p44/43MAPK (ERK1/2) (Thr202/Tyr204), and anti–
phospho-mammalian target of rapamycin (mTOR; Ser2448) from Cell
Signaling (Danvers, MA); and anti-BrdU and anti–β-tubulin from Santa
Cruz Biotechnology (Santa Cruz, CA).
Bromodeoxyuridine Incorporation Assay
Cells were cultured on a 96-well plate (PerkinElmer, Waltham, MA)
with the indicated medium. Subsequently, the medium was replaced to
medium with 5-bromo-2-deoxyuridine (BrdU) and incubated for 70
(serum containing) or 120 minutes (serum starvation). After incuba-
tion, the BrdU labeling medium was removed, and the cells were
washed with phosphate-buffered saline (PBS) twice for 5 minutes each.
The cells were then fixed with 70% ethanol containing glycine at
−20°C for 30 minutes. Next, the cells were washed three times with
PBS and incubated in 2 M HCl at room temperature for 60 minutes.
Subsequently, the cells were rinsed and treated with PBS containing
3% bovine serum albumin (BSA) at room temperature for 30 minutes
and incubated with anti-BrdU antibodies. The primary antibody
was detected by A594 Alexa Fluor secondary antibodies (Invitrogen).
After Hoechst staining at 4°C for 15 minutes, cells were washed again.
Finally, the images were captured and quantified by using ArrayScan 4.5
high-content-screening system (Cellomics, Pittsburg, PA).
Tandem Affinity Purification and Protein Identification
by Mass Spectrometry
For tandem affinity purification (TAP-TAG) and mass spectrometry
analysis, we separated and amplified NTN4 full-length sequence to five
fragments based on functional domains (Figure W4B).
Using the lentivirus system, we successfully obtained U251MG cells
expressing FLAG/HA–tagged fragments and full-length NTN4 comple-
mentary DNA (cDNA). Immunofluorescence and immunoblot analysis
with anti-HA antibody were performed to confirm target sequence ex-
pression (Figure W4, B and C). U251MG cells expressing the indicated
protein were lysed in RIPA buffer (50 mM Tris-HCl buffer pH 7.4,
containing 150 mM NaCl, 1% NP-40, 0.1% SDS), and lysates were
incubated with anti-FLAGM2Affinity Gel (Sigma-Aldrich) at 4°C over-
night. Subsequently, Sepharose beads were washed with RIPA buffer for
five times usingmicro bio-spin column (Bio-Rad, Hercules, CA). FLAG-
containing proteins were eluted by incubating the Sepharose beads with
3× FLAG peptide (Sigma-Aldrich) for 30 minutes on ice. Eluates were
incubated with anti-HA Affinity Gel (Sigma-Aldrich) at 4°C for 2 hours.
Sepharose beads were washed for five times in spin column, and proteins
were eluted with Laemmli sample buffer for 5 minutes on ice.
For identification, proteins were separated by SDS-PAGE and visu-
alized by silver staining followed by in-gel digestion with trypsin and
liquid chromatography–tandem mass spectrometry analysis of the
resulting peptides as previously described [26]. The nonspecifically in-
teracting proteins identified from control samples were excluded from
the identification lists of interacting proteins for full-length NTN4 and
fragments of it to create the final list of candidate interacting proteins
(Supplemental Data Set).
Statistical Analysis
All numerical values represent mean ± SE or SD. Statistical signifi-
cance was determined with the nonparametric Mann-Whitney U test.
Lentiviral transfection, quantitative real-time polymerase chain
reaction (Q-RT-PCR), migration assay, apoptosis assay, immuno-
fluorescence, and immunoblot analysis were carried out using standard
protocols, and these are described in detail in Supplemental Materials
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and Methods. Bioinformatics analyses were performed as described
previously [27,28], see Supplemental Materials and Methods for details.
Results
NTN4 Regulates Glioblastoma Cell Proliferation and
Migration in a Concentration-Dependent Manner
NTN4 is highly expressed in astrocytes [11–13]. In vitro and in vivo
studies have also revealed that NTN4 regulates tumor cell growth
in various cancer types [15,18,19]. It is therefore possible that glio-
blastoma, the malignant tumor stage of astrocyte, responds to NTN4.
We first investigated the expression of NTN4 in astrocytes and
three glioblastoma cell lines by Q-RT-PCR. We detected decent levels
of NTN4 gene expression in three invasive glioblastoma cell lines:
U251MG, U373MG, and U87MG. However, the expression level
of NTN4 in glioblastoma cells was lower than in astrocytes (Fig-
ure 1A). We then analyzed the behavior of glioblastoma cell lines after
suppression of NTN4 expression. By using the lentiviral short hairpin
RNA (shRNA) system, we successfully decreased NTN4 expression
levels in the three glioblastoma cell lines. Three efficient shRNAs of
NTN4 were identified by both Q-RT-PCR (Figure 1B) and immuno-
fluorescence (Figure 1C).
BrdU incorporation assay revealed that the suppression of NTN4
expression in U251MG cells inhibited cell proliferation (Figure 1D).
Using wound closure assays, we determined that the reduction of
NTN4 expression suppressed U251MG cell motility (Figure 1E). It
has been found that NTN4 acts as a survival factor for lymphatic
endothelial cells [15]. Therefore, we investigated the effects of reduced
Figure 1. NTN4 regulates glioblastoma cell proliferation and migration in a concentration-dependent bell-shaped manner. (A) Astrocytes
and glioblastoma cell lines express NTN4. Using Q-RT-PCR, NTN4 expression levels were determined in astrocytes and three invasive
glioblastoma cell lines: U87MG, U251MG, and U373MG. Glioblastoma cells have a lower expression of NTN4 than astrocytes in vitro.
(B and C) U251MG cells were infected by lentivirus harboring NTN4 shRNAs. After puromycin selection for 72 hours, Q-RT-PCR was per-
formed to detect the expression of NTN4. NTN4 shRNAs resulted in NTN4 mRNA reduction of approximately 80% for shRNA1, 95% for
shRNA3, and 87% for shRNA4 (B). The silencing effects of these three shRNAs were also detected by immunofluorescence (C). (D-F) Cells
expressing NTN4 shRNAs were used for proliferation assay, migration assay, and apoptosis assay. Mitogenic rate, migration distance, and
survival rate of NTN4-silenced cells were compared with nontransfected cells (wt) or cells transfected with nontargeting shRNA (Scr). In
the apoptosis assay, cells cultured in 10% serum-containing medium were used as positive control. Suppression of NTN4 gene expres-
sion in U251MG cells significantly reduced cell mitogenicity, migration, and increased apoptosis caused by serum deprivation. (G and H)
U251MG cells were cultured in serum-free medium for 4 hours and then cultured in the presence of recombinant NTN4 with the indi-
cated concentrations. Recombinant NTN4 was reapplied every 24 hours for 48 hours. Cells were then used for proliferation assay. NTN4
promoted U251MG cell proliferation at 50 and 200 ng/ml, but it inhibited cell proliferation at 3 μg/ml (G). U251MG cells were cultured in
serum-free medium overnight and then used for the wound closure assays in the presence of recombinant NTN4 as in the indicated
concentration. NTN4 promoted U251MG cell migration at 50 and 200 ng/ml. However, 5 μg/ml NTN4 had no significant effect on U251MG
cell migration (H). Mean ± SE, n ≥ 3. **P < .01. *P < .05.
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NTN4 expression on glioblastoma cell apoptosis by TUNEL assay.
We found that inhibition of NTN4 expression significantly increased
glioblastoma cell apoptosis caused by serum deprivation (Figure 1F ).
In addition, suppression of NTN4 expression also reduced U373MG
and U87MG cell proliferation, inhibited U373MG cell motility, and
increased U373MG cell apoptosis caused by serum deprivation (Fig-
ure W1). NTN4 may therefore play an important role in promoting
glioblastoma cell proliferation and migration.
To further assess the role of NTN4 on the migration and prolifera-
tion of glioblastoma cells, NTN4 was overexpressed in U251MG cells.
We used two overexpression methods and successfully obtained two
NTN4-overexpressing U251MG cell populations (NTN4.pLVX and
NTN4.pcDNA3). Q-RT-PCR was performed to confirm NTN4
gene overexpression at the mRNA level (Figure W2A). BrdU incor-
poration assays and wound closure assays revealed that stable NTN4
overexpression alters neither U251MG cell proliferation (Figure W2B)
nor migration (Figure W2C ). These results are in agreement with
studies on prostate cancer, breast cancer, and colorectal carcinoma
[15,16,18] but are not consistent with the effect of silencing NTN4
in glioblastoma cells.
The reason why we did not observe any effects on cell proliferation
and migration with stable overexpression may arise from clonal selec-
tion and/or cell adaptation to increased NTN4 expression during
selection process. Therefore, we assessed U251MG cell proliferation
(Figure 1G) and migration (Figure 1H) by using increasing concentra-
tions of exogenous NTN4. NTN4 promoted cell proliferation and
migration concentration dependently with a maximum at 200 ng/ml.
However, 5 μg/ml NTN4 did not display any effect on cell migration
and 3 μg/ml significantly inhibited cell growth. These data imply that
the effects of NTN4 on glioblastoma cells are concentration dependent.
NTN4/ITGB4 Interaction Promotes Glioblastoma
Cell Proliferation
Similar to NTN1, the biphasic function of NTN4 on glioblastoma
cells may arise from the binding to different receptors. To identify
the receptors that mediate the biologic functions of NTN4, we
first used Q-RT-PCR to determine which previously known receptors
of the NTN family are expressed in the U251MG, U87MG, and
U373MG cells. We found that these three glioblastoma cells express
Figure 2. NTN4/ITGB4 interaction promotes glioblastoma cell proliferation. (A) U251 cells expressing empty vector or FLAG/HA–tagged
NTN4 were cultured to 50% confluence and were subsequently lysed for immunoprecipitation. After immunoprecipitation with anti-HA
agarose, ITGB4 was detected in immunoprecipitates of FLAG/HA–tagged NTN4. Immunoprecipitates of empty vector and cell lysates
were set as negative control and positive control, respectively. (B) U251MG cells were cultured to 50% confluence and were incubated
with conditioned medium from either control or FLAG/HA–tagged NTN4 (NTN4FH)–expressing cells as described in Supplemental
Materials and Methods, and then used for immunofluorescence. Micrographs of ITGB4 (red) and HA (green) in U251MG were obtained
using a confocal laser scanning microscope. Yellow indicates the colocalization of ITGB4 and NTN4. (C) U251 cells expressing the
indicated gene or shRNAs were cultured in 96-well plates for 2 days and then used for the proliferation assay. Neither NTN4 over-
expression nor ITGB4 overexpression alone promoted U251MG cell growth. Combined overexpression of NTN4 and ITGB4 increased
cell proliferation by approximately 30%. (D) U251 cells expressing the indicated gene or shRNAs were used for proliferation assay.
Suppression of ITGB4 expression in NTN4-silenced U251MG cells did not further reduce cell proliferation. Complete suppression of
NTN4 expression, NTN4sh3, slightly increased the proliferation of ITGB4-silenced U251MG cells. (E) Suppression of ITGB4 expression
leads to less mitogenic rate in NTN4-overexpressing U251MG cell than in control cells. (F) Suppression of UNC5B expression in
U251MG cells reduced cell mitogenic ability. Exogenous addition (3 μg/ml) of NTN4 inhibited cell proliferation in control cells but not
in UNC5B-silenced cells. Mean ± SE, n ≥ 3. **P < .01. *P < .05.
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several receptors of NTN1 (Figure W3). Next, we applied TAP-TAG
combined with protein identification by mass spectrometry by using
NTN4 as a bait (Figure W4 and Supplemental Data Set). In the
process, we reliably identified integrin β4 (ITGB4) as a partner inter-
acting with NTN4 by immunoprecipitation (Figure 2A) and observed
that NTN4 and ITGB4 colocalized at the edge of U251MG cell
(Figure 2B).
Recent studies have revealed that ITGB4 is involved in tumor pro-
gression [29], and many glioblastoma cell lines express ITGB4 [30].
All of U87MG, U251MG, and U373MG cells express ITGB4, but
the expression levels of ITGB4 in these three cell lines are different. A
previous report described that U373MG cells migrate and proliferate
slightly faster than U87MG cells in vitro and leads to poorer survival
than U87MG in vivo [31]. To investigate the function of ITGB4
and NTN4, we overexpressed them either separately or together (Fig-
ure W5A). We found that neither NTN4 overexpression nor ITGB4
overexpression alone altered U251MG cell proliferation. However,
co-overexpression of ITGB4 and NTN4 increased glioblastoma cell
growth slightly but significantly (Figure 2C).
We subsequently knocked down the expression of ITGB4 in the
glioblastoma cell lines. Suppression of ITGB4 inhibited the prolifera-
tion of both U87MG and U373MG cell. Nontargeting shRNA was
used as control (Figure W5, B-E). We then transduced the most effi-
cient shRNAs of ITGB4 and NTN4 into U251MG cells in combina-
tion (Figure W5, F and G ). BrdU incorporation assays revealed that
suppression of ITGB4 in U251MG cells inhibited cell growth but
did not further reduce the proliferation rate of NTN4-silenced cells.
These data imply that ITGB4 mediates NTN4’s effects in the promo-
tion of cell proliferation. Interestingly, an almost complete suppression
of the expression of NTN4 (NTN4sh3) even slightly increased the
mitogenic rate of ITGB4-suppressed cells (Figure 2D). One explana-
tion for this is that, after silencing ITGB4, the remaining NTN4 inter-
acts with other potential lower-affinity receptors, which induce negative
effects for proliferation. To obtain support for this hypothesis, we sup-
pressed ITGB4 expression in both control and NTN4-overexpressing
U251MG cells (Figure W5H). BrdU incorporation assay showed that
overexpression of NTN4 in ITGB4-suppressed U251MG cells led to
a lower proliferation rate compared to cells with normal ITGB4 ex-
pression level (Figure 2E). This observation is in accordance with the
hypothesis that NTN4 may negatively regulate cell proliferation when
not bound to ITGB4.
Because the complex of NEO1 and UNC5B has been observed
to mediate the angiogenesis inhibition of NTN4 [16,32], we investi-
gated the role of UNC5B in cell growth inhibition of NTN4 by using
UNC5B shRNAs (Figure W5I ). Suppression of UNC5B expression
decreased U251MG cell proliferation. However, higher concentrations
of NTN4 were not able to further inhibit glioblastoma cell proliferation
(Figure 2F ).
NTN1 binds also to ITGB4 [9]. Therefore, we asked whether NTN4
competes with NTN1 for binding to ITGB4. By using the over-
expression of either tagged or native NTNs, we revealed that NTN1
and NTN4 do not compete with each other in binding to ITGB4
(Figure W6). Similarly, we found that both NTN1 and NTN4 promote
cell proliferation, but neither NTN1 nor NTN4 can compensate each
other for the growth-promoting effects. Furthermore, combined
overexpression of NTN1 and NTN4 did not have any effect on cell
Figure 3. NTN4 expression is downregulated in glioblastoma specimens and associates with reduced patient survival. (A) On the basis
of 425 primary GBM tumors from TCGA [27,33], bioinformatics analysis revealed that the expression of NTN4 was reduced to 33% in
grade 4 glioblastoma, compared with normal brain tissue. (B) Kaplan-Meier survival analysis showed that the low expression of NTN4
predicts poor patient survival. Black line represents all glioblastoma samples with low expression of NTN4 compared with normal tissue
(fold change < 0.5), and gray line represents a group of glioblastoma samples which have similar expression of NTN4 to the normal
brain tissue. Dashed lines represent 0.95 confidence intervals for the curves with the corresponding color. P < .043. (C) The expression
of ITGB4 increased 2.9-fold in grade 4 glioblastoma, compared with normal brain tissue. (D) Kaplan-Meier survival analysis showed that
the upregulated expression of ITGB4 predicts poor patient survival. Gray line represents all glioblastoma samples with high expression
of ITGB4 compared with normal tissue (fold change > 3), and black line represents a group of glioblastoma samples that have similar
expression of ITGB4 to the normal brain tissue. P < .029. (E) The expression of UNC5B does not significantly change in glioblastoma
compared with the normal brain tissue.
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proliferation, and silencing of the expression of both NTN1 and NTN4
had an additive effect on cell proliferation (Figure W7).
NTN4 Expression Is Downregulated in Clinical Glioblastoma
Specimen and Associates with Patient Survival
In vitro data suggest that NTN4 may act as a stimulator or an in-
hibitor of glioblastoma cell proliferation through binding to different
receptors. To investigate the role of NTN4 and ITGB4 in glioblastoma
tissues, we analyzed the expression levels of primary tumors from The
Cancer Genome Atlas – Glioblastoma multiforme (TCGA-GBM) re-
pository [27,28,33]. NTN4 is expressed less in grade 4 glioblastoma
than in normal brain tissue (Figure 3A). In addition, we analyzed
NTN4 expression in relation to the survival time of the patients with
grade 4 glioblastoma. We found that low expression of NTN4 predicts
poor patient survival time (Figure 3B). To confirm these results, we
used the Oncomine database and two published reports [34,35]. The
expression of NTN4 decreased after glioma progression from grade 2
to grade 4 (Figure W8A). However, most glioma cell lines express
NTN4 (Figure W8B). These data suggest that proper concentration
of NTN4 is beneficial for glioma cells, whereas high concentrations
of NTN4 may have negative effects on glioma progression.
Interestingly, the expression of ITGB4 is significantly increased in
grade 4 glioblastoma (Figure 3C ), and the up-regulation of ITGB4
expression predicts poor patient survival time (Figure 3D). However,
the expression of UNC5B has no significant change in GBM specimens
compared with normal brain tissue (Figure 3E).
NTN4/ITGB4 Interaction Activates AKT/mTOR
Signaling Pathways
AKT and ERK1/2 phosphorylation have been linked to ITGB4-
mediated cell proliferation [36,37], and a recent study has shown
that NTN4 activates S6K [15]. Therefore, we assessed the effect
of NTN4 on the activation of the MAP kinase, AKT, and mTOR
signaling pathways.
Figure 4. NTN4/ITGB4 interaction activates AKT/mTOR signaling pathways. (A) U251 cells expressing NTN4 shRNAs were cultured in
serum-free medium for 12 hours, followed by immunoblot analysis as indicated. U251 cells expressing NTN4 shRNAs displayed reduced
phosphorylation of AKT andmTOR but slightly increased phosphorylation of ERK. Chart illustrates the relative phosphorylation levels of AKT,
mTOR, and ERK. (B) NTN4 concentration-dependently increased AKT and mTOR phosphorylation. U251MG cells were cultured in serum
free medium for 12 hours and then incubated with increasing concentrations of exogenous recombinant NTN4 for 30 minutes, followed by
immunoblot analysis as indicated. Concentrations of 5 and 50 ng/ml NTN4 significantly increased AKT and mTOR activation in U251MG
wild-type cells and scrambled transfected control cells. Chart illustrates the relative phosphorylation levels of AKT and mTOR. (C) Con-
centrations of 5 and 50 ng/ml NTN4 were not able to stimulate AKT phosphorylation in ITGB4-silenced U251MG cell. Chart illustrates the
relative phosphorylation levels of AKT. β-Tubulin was used as loading control. Mean ± SE, n ≥ 3. **P < .01. *P < .05.
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Suppression of NTN4 expression in U251MG significantly reduced
AKT and mTOR phosphorylation, whereas it slightly increased ERK1/
2 phosphorylation (Figure 4A). Thirty minutes after exogenous addi-
tion of NTN4, U251MG cells displayed concentration-dependent
activation of AKT and mTOR (Figure 4B). This suggested that
NTN4 promotes glioblastoma cell growth by stimulating the phos-
phorylation of AKT-mTOR signaling pathway.
ITGB4 has been shown to induce AKT-mTOR signaling [38,39],
and mTOR plays a crucial role in cell proliferation [40,41]. Insulin
receptor substrates participate in the ITGB4-AKT signaling pathway
[37], and these molecules also appeared in the list of interacting
candidates for NTN4 (Supplemental Data Set). Therefore, we in-
vestigated the role of NTN4 in ITGB4 mediated AKT-mTOR
signaling pathway. Addition of recombinant NTN4 increased AKT
phosphorylation in control cells. However, it was not able to acti-
vate AKT in ITGB4-suppressed U251MG cells. This indicates that
ITGB4 mediates NTN4-induced AKT-mTOR phosphorylation
(Figure 4C ).
Discussion
NTN4 was discovered a decade ago as an axon guidance cue [11,13].
Recent studies have described that NTN4 regulates endothelial cell
adhesion, migration, proliferation, and apoptosis and that its effects
correlate with its concentration [5,15,16,42]. In cancer cells, NTN4
can act as a modulator of tumor growth, angiogenesis, and metastasis
[15,18,19,21]. As a functional molecule in CNS, high expression of
NTN4 has been found in astrocytes and at the invading edge of glio-
blastoma specimens [12,13,20]. However, the functions and molecular
mechanisms of NTN4 in glioblastoma are not clear yet.
So far, many studies support the hypothesis that NTNs, especially
NTN1, have biphasic functions during development [1,2,6]. In the
present study, we provide evidence that NTN4 plays a dual role
in the modulation of glioblastoma cell proliferation. The mitogenic
facilitation of glioblastoma cells may convert to inhibition of prolifera-
tion at higher NTN4 concentrations in a bell-shaped manner. This is
consistent with the result that NTN4 is downregulated in glioblastoma
specimen and predicts patient survival. It is also consistent with the
dual role of NTN4 in other tumor cell lines [19].
The receptors and downstream signaling pathway of NTN4 me-
diating these functions have been largely unknown. ITGB4, the
β-subunit of integrin heterodimers, is predominantly expressed in
epithelial cells. It is upregulated during tumor progression and patho-
logic angiogenesis [43]. In the CNS, ITGB4 is expressed strongly in
astrocytes, and it is upregulated during glioma progression [44,45],
indicating that ITGB4 plays an integral role in glioblastoma. Exon-
array analysis with more than 400 GBM primary tumors revealed
that the expression of ITGB4 is upregulated in grade 4 glioblas-
tomas, and it predicts poor patient survival whereas it negatively
associates with NTN4 expression. We discovered that ITGB4 binds
to NTN4 and mediates the positive effects of NTN4 on glioblas-
toma cell proliferation. Interestingly, suppression of NTN4 expres-
sion in ITGB4-silenced cells slightly increases cell mitogenicity,
and NTN4 overexpression leads to mitogenic inhibition in ITGB4-
silenced glioblastoma cells. These results suggest that there are other
mechanisms mediating the negative effects of NTN4. So far, the com-
plex of NEO1 and UNC5B has been identified to participate in
the antiangiogenic activity of NTN4 [16,18,32]. Our results indicate
that UNC5B mediates the negative effects of NTN4 on glioblastoma
cell proliferation.
Although NTN4 and ITGB4 interaction induces glioblastoma cell
proliferation, their expression levels in glioblastomas correlate negatively.
In addition, the expression levels of NTN4 and ITGB4 are related to
patient survival positively and negatively, accordingly. Regarding the
dual role of NTN4 in glioblastoma cells and its potential inhibitory
effects on angiogenesis at high concentrations [16,18], we propose a
mechanism for NTN4 and ITGB4 in glioma progression. At the initial
stage of glioma progression, the concentration of NTN4 in the extra-
cellular environment is relatively high. Glioma cells express low levels
of ITGB4, which is sufficient to respond to high concentrations of
NTN4. Meanwhile, high concentrations of NTN4 have the ability to
interact with UNC5B. Therefore, NTN4 may reduce cell prolifera-
tion through UNC5B and maintain the balance of glial cell proliferation.
During tumor progression, glioma cells reduce their NTN4 expression.
Figure 5. Interplay mechanism between NTN4 and ITGB4 during glioma progression. At the initial stage of glioma progression, NTN4
concentration stays relatively high in extracellular environment. High concentrations of NTN4 have an ability to reduce cell proliferation
through UNC5B. During progression, glioma cells reduce NTN4 expression to prevent the negative effects on glioma cell growth induced
by NTN4. In parallel, ITGB4 expression increases. In this way, excessive ITGB4 makes glioblastoma cells hyperresponsive to low concen-
trations of NTN4 for keeping AKT/mTOR phosphorylation and glioma cell proliferation.
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Because of the unaltered expression of UNC5B, decreased NTN4 ex-
pression endows glioma cells with at least two benefits: First, it helps
glioma cells to escape from NTN4 induced growth reduction. Second,
glioma tumor is relieved from potential angiogenesis inhibition induced
by high concentration of NTN4. In parallel, ITGB4 expression in-
creases. In this way, excessive ITGB4 may make glioblastoma cell hyper-
responsive to low concentrations of NTN4 and maintain glioma cell
proliferation (Figure 5).
The complicated functions of NTN4 in glioblastoma cells indicate
that NTN4 may be associated with multiple signaling pathways. In
cancer cells, ITGB4 interacts with several growth factor receptors in-
cluding ErbB2, epidermal growth factor receptor, and Met [46–48].
These interactions lead to enhanced receptor tyrosine kinase sig-
naling and associate ITGB4 with tumor progression and invasion.
ITGB4 promotes tumor progression through three signaling path-
ways: Ras-ERK pathway, PI3K-AKT pathway, and NFAT pathway
[36,37,49]. Meanwhile, it has also been found that ITGB4 activates
the AKT-mTOR signaling pathway, and insulin receptor substrates
act as components in ITGB4-transduced AKT phosphorylation [37–
39]. We have identified insulin receptor substrates in the interact-
ing candidate list of NTN4. These results indicate that NTN4 may
act as a stimulator in ITGB4 activation. Furthermore, a recent study
reported that NTN4 activates S6K to stimulate protein synthesis
[15]. These observations suggest that NTN4 activates the ITGB4-
transduced AKT-mTOR signaling pathway. In the current work, we
provide evidence that NTN4 induces phosphorylation of AKT and
mTOR through ITGB4. As mTOR has been found to associate with
glioblastoma cell proliferation, apoptosis, and transformation [50–52],
it is likely that NTN4 promotes glioblastoma cell proliferation through
ITGB4-transduced PI3K-AKT-mTOR signaling pathway.
In summary, the complicated functions of NTN4 in GBM cells
are mediated by different receptors and multiple signaling pathways.
The observation of ITGB4 and NTN4 interaction provides a novel
pathway for promotion of tumor growth. This suggests that block-
ing ITGB4 may be a promising therapy method for treating glioblas-
toma and that NTN4/ITGB4 interaction possibly provides a way to
modulate ITGB4 signaling.
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Supplemental Materials and Methods
Total RNA Extraction, Reverse Transcription, and Real-time
Reverse Transcription–PCR
Total cellular RNA was isolated and purified using RNeasy Mini Kit
(Qiagen, Hilden, Germany). Reverse transcription was carried out with
random hexamer primers (Invitrogen) and SuperScript III reverse tran-
scription (Invitrogen) using 1.0 μg of total RNA according to the
manufacturer’s instructions. The cDNA products were amplified
by TaqMan Assays-on-Demand gene expression products (Applied
Biosystems, Foster City, CA), TaqMan Universal PCR Master Mix
(Applied Biosystems), and CFX96 Real-time PCR Detection System
(Bio-Rad). Levels of gene expression were determined by ΔΔCTmethod,
with the results being expressed as mRNA expression levels normalized to
the levels of a gene with a constant expression (GAPDH).
Vectors and Expression Constructs
pRK5-FLAG /HA (pRK5-FH) plasmid was provided byDrGiancotti’s
laboratory, Memorial Sloan-Kettering Cancer Center [1]. pRK5-FH
contains EcoRI and BamHI restriction sites for cloning the target gene
and C-terminal Flag and HA tag.
The indicated fragments or full-length gene were amplified and cloned
to pRK5-FH. In constructs missing the signal sequence, CD33 signal
sequence coding cDNA was cloned 5′ to the coding region of each
construct. Next, by using a pair of primers recognizing pRK5 plasmid
DNA sequence upstream of target gene and downstream of FLAG-
HA, we amplified all the constructs with FLAG/HA tag from pRK5
plasmid, and then cloned them to pLVX-puro (Clontech) plasmid for
lentiviral expression. Full-length human NTN1 and NTN4 were cloned
to both pLVX-puro and pcDNA3 (Invitrogen) plasmid for subsequent
assays. All constructs were confirmed by DNA sequencing. Details on
the cloning are available on request.
Transfection of Cells
Cells were cultured on six-well plates to 50% to 80% confluence
and transfected using 2 μg of plasmid DNA and 6 μl of FuGENE 6
transfection reagents for each transfection according to the manufac-
turer’s instructions (Boehringer Mannheim, Mannheim, Germany).
Stably transfected cells were selected with ∼0.8 mg/ml G418 (Gibco/
Invitrogen) in complete medium. The expression levels of each indi-
cated gene in transfected cells were analyzed by Q-RT-PCR.
Lentiviral Silencing/Overexpression of Gene Expression
Plasmids expressing shRNAs targeted against the indicated gene
were obtained from the RNAi Consortium through Open Biosystems
(hairpin-pLKO.1 vector). Five different constructs for each gene were
tested. A nontargeting scrambled construct was used as control for
nonspecific effects (scrambled-pLKO.1 vector). Plasmids harboring
the indicated gene were constructed as described above. pLVX-puro
empty vector was used as a control.
To produce recombinant lentivirus particles, 293FT producer cells
were cotransfected with the packaging/envelope plasmids (pCMVdr8.74
and pMD2-VSVG; Addgene, Cambridge, MA) and target plasmids by
using the Lipofectamine (Invitrogen) transfectionmethod.Normal com-
plete culture medium (high-glucose Dulbecco modified Eagle medium
[DMEM]) was changed to the 293FT cells 24 hours after transfection.
Subsequently, 48 hours later, the viral supernatants were harvested and
filtered through a 0.45-μm filter. The titer of the virus was investigated.
After a 24-hour infection with virus, the supernatants were replaced
with complete medium (DMEM) for the subsequent assays. For stable
shRNA expression, the infected U251MG cells were subjected to selec-
tion with 2 μg/ml puromycin for 72 hours. The efficiency of the trans-
duction was measured by monitoring the indicated gene expression.
Scratch-Induced In Vitro Wound Closure Assay
Cells were plated in 24-well tissue culture plate at a concentration
of 30,000 cells and maintained under the indicated conditions for
3 days. After the cell cultures reached ∼90% confluence, the tip of
a 1000-μl micropipette was used to scratch the cells, creating linear
and cross-shaped scratches. Cell layers were washed twice with PBS
to remove floating cells and medium. The medium was replaced by
DMEM containing 0.5% serum for an additional 12-hour incuba-
tion. Cell migration was photographed at the edge where the scrape
was introduced at the time point of 0 and 8 hours using Axiovert 200
inverted epifluorescence microscope (Carl Zeiss). The migration rate
was analyzed with the ImageJ program (National Institutes of Health,
Bethesda, MD).
Serum Deprivation–Induced Apoptosis Assay
Cells were cultured on glass coverslips overnight and then changed
the medium to serum free DMEM and cultured for 72 hours. When
cells started to float up, the coverslips were washed with PBS and fixed
with 4% paraformaldehyde in PBS for 20 minutes. The cells were then
subject to TUNEL labeling by using In Situ Cell Death Detection Kit
(Roche, Switzerland) according to the manufacturer’s instructions.
After several washing steps, the coverslips were washed once inwater and
then mounted with VECTASHIELD antifading reagent (Vector Lab-
oratories, Burlingame, CA). Nuclei were visualized by 4′,6-diamidino-
2-phenylindole staining. The images were captured using the 20× objective
of the Axioplan microscope (Carl Zeiss, Inc, Thornwood, NY), acquired
with AxioCamHRc camera (Carl Zeiss) and AxioVision3.1 software
(Carl Zeiss).
Immunofluorescence
Cells were cultured on glass coverslips for the indicated times. For
observing the colocalization of ITGB4 and NTN4 in U251MG cell,
U251MG cells were incubated with the conditioned medium from
either control or HA-tagged NTN4-expressing cells on ice for 1 hour.
Cells were washed with PBS and fixed with 4% paraformaldehyde in
PBS for 20 minutes and then incubated in permeabilization buffer
(0.1% Triton X-100 in PBS) for 15 minutes on ice. Subsequently,
the cells were washed three times with PBS for 5 minutes each and
treated with Dulbecco PBS containing 3% BSA at room temperature
for 30 minutes. The cells were rinsed and incubated with primary
antibody diluted in Dulbecco PBS containing 3% BSA at room tem-
perature for 1 hour. After washing with PBS, the cells were incubated
with Alexa Fluor secondary antibodies (Invitrogen) diluted in Dulbecco
PBS containing 3% BSA at room temperature for 30 minutes. After
several washing steps, the coverslips were washed once in water and
then mounted with Mowiol-mounting medium (Calbiochem/Merck,
Darmstadt, Germany) containing 6 mg/ml DABCO (Sigma) as anti-
fading reagent. Nuclei were visualized by Hoechst (Sigma) staining.
The images were captured using the Axioplan microscope (Carl Zeiss),
laser scanning confocal microscope (Zeiss LSM 510 Meta), and ac-
quired with AxioCamHRc camera (Carl Zeiss), AxioVision3.1 software
(Carl Zeiss), and LSM software at the Biomedicum Imaging Unit of
the University of Helsinki.
SDS-PAGE and Immunoblot Analysis
Cells were lysed in RIPA buffer supplemented with protease inhibi-
tors (Roche). SDS-PAGE was performed using commercial 4% to 20%
gradient Tris-HCl polyacrylamide gels (Lonza). Electrophoretically
separated proteins were transferred onto nitrocellulose membranes
(PROTRAN; Schleicher and Schuell, Keene, NH) by semidry blot
analysis system (Bio-Rad). The membranes were subsequently washed
three times with 0.05% Tween-20/Tris-buffered saline and incubated
with the primary antibodies in 5% BSA/0.05% Tween-20/Tris-buffered
saline at 4°C overnight. Membranes were washed twice for 10 minutes
each. HRP-conjugated secondary antibodies (Santa Cruz Biotechnology)
were then diluted in 5% BSA/0.05% Tween-20/TBS and incubated
with the membrane at 4°C for 1 hour. After several washing steps,
the detection was performed using enhanced chemiluminescence re-
agents (GE Healthcare, United Kingdom). The images were obtained
using an x-ray film (Fujifilm, Tokyo, Japan) and Kodak X-OMAT
2000 equipment (Kodak, Rochester, NY).
Phospho-specific Western blot analysis was performed following
the manufacturer’s instructions (Cell Signaling Technology, Danvers,
MA). Protein concentrations were measured using a bicinchoninic acid
kit (Thermo Scientific, Rockford, IL). Equal amounts of total protein
were loaded per lane.
Band intensity quantification was carried out using ImageJ software.
Bioinformatics Analysis
Exon array data for 425 primary GBM samples and 10 normal brain
samples were downloaded from the TCGA repository and preprocessed
at gene level by Multiple Exon Array Preprocessing (MEAP) algorithm
[2]. All data analyses, such as statistical tests and Kaplan-Meier survival
estimates, were done with the Anduril framework [3]. In the survival
analyses, we used 393 samples that had survival end time in the TCGA
GBM repository. Fold change (FC) values were calculated by taking
the median and used in grouping for Kaplan-Meier survival analysis,
where patients were divided into groups denoted by “−1” (underexpres-
sion, FC < 0.5), “1” (overexpression, FC > 3), and “0” (stable expres-
sion). Survival P values were calculated with the log rank test, and the
threshold used in our analysis was P < .05.
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Supplemental Data Set
The peptide data obtained with mass spectrometry were used to
identify proteins with Mascot search engine. The searches were done
against the SwissProt database. The identification lists for negative
control, full-length NTN4, and each of the fragments are shown.
Figure W1. Suppression of NTN4 expression inhibit glioblastoma cell proliferation and motility. (A, B) Suppression of NTN4 gene
expression in U373MG cells significantly reduced both cell mitogenic ability and motility compared with cells transfected with nontargeting
scrambled control (Scr). (C) Suppression of NTN4 expression increased U373MG cell apoptosis caused by serum deprivation compared
with the nontargeting control (Scr). Cells cultured in 10% serum were set as positive control. (D) Suppression of NTN4 gene expression
also reduced U87MG cell mitogenicity. Mean ± SE, n ≥ 3. **P < .01. *P < .05.
Figure W2. Stable overexpression of NTN4 has no significant effects on U251MG cell proliferation and migration. Q-RT-PCR was used to
detect the expression of NTN4 at the mRNA level in NTN4-overexpressing U251MG cells. The NTN4 mRNA is increased ∼50-fold in
NTN4.pcDNA3-transfected U251MG cell and ∼550-fold in NTN4.pLVX-transfected U251MG cell (A). The wild-type, empty vector control
and NTN4-overexpressing U251MG cells proliferated (B) and migrated (C) at comparable rates.
Figure W3. The expression of various receptors of NTN1 in glio-
blastoma cell lines. U251MG, U87MG, and U373MG cells were
cultured to ∼50% confluence and subsequently used for Q-RT-
PCR. The expression levels of NTN1 receptors were compared with
the expression of GAPDH. (A) U251MG cells express ITGA3, ITGA6,
ITGB4, UNC5C, and UNC5D at decent levels; U251MG also express
NEO1 and UNC5B at low levels. However, DCC and UNC5A were
absent in U251MG. (B) U87MG cells express ITGA3, ITGA6, NEO1,
and UNC5B at decent levels and express DCC and ITGB4 at low
levels. However, UNC5A, UNC5C, and UNC5D are absent in
U87MG. (C) U373MG cells express ITGA3, ITGA6, ITGB4, and
UNC5C at decent levels and express NEO1, UNC5B, and UNC5D
at low levels. However, DCC and UNC5A are absent in U373MG.
Figure W4. TAP-TAG and mass spectrometry analysis. (A) We separated NTN4 full-length sequence to five fragments based on func-
tional domains. (B, C) We successfully obtained U251MG cells expressing FLAG/HA–tagged peptides and full-length NTN4 cDNA. Immuno-
fluorescence and immunoblot analysis with anti-HA antibody were performed to confirm target sequence expression.
Figure W5. The expression level of NTN4 and ITGB4 in various cell lines and suppression of ITGB4 reduce U87MG and U373MG cell pro-
liferation. (A) Q-RT-PCR was used to detect the expression of NTN4 and ITGB4 at mRNA level in NTN4/ITGB4 transfected cells. The expres-
sion of NTN4 increased ∼70-fold more in NTN4.pLVX transfected U251MG cells and ∼100-fold for NTN4/ITGB4 combined transfected
U251MG cells. The expression of ITGB4 increased∼15-fold in ITGB4.PFB transfected U251MGcells and∼20-fold in NTN4/ITGB4 combined
transfected U251MG cells. (B, C) Knocking down ITGB4 in U87MG reduced cell proliferation. (D, E) Suppression of ITGB4 in U373MG
inhibited cell proliferation. (F) Two most efficient shRNAs of ITGB4 significantly inhibited ITGB4 expression in U251MG at protein level.
(G) We successfully suppressed the expression of ITGB4 and NTN4 either alone or together in U251MG cells at the mRNA level. (H) We
obtained U251MG cell lines with ITGB4 silencing and NTN4 overexpression. (I) Q-RT-PCRwas performed to detect UNC5B silencing effects
in U251MG cells. UNC5B shRNAs resulted in UNC5B mRNA reduction of approximately 96% for shRNA2 and 94% for shRNA3.
Figure W6. NTN4 binds to ITGB4 independently of NTN1/ITGB4 interaction. (A, B) We established two U251MG cell lines overexpressing
NTNs, as either tagged or native proteins (NTN1FH/NTN4; NTN4FH/NTN1). Meanwhile, tagged NTN1-overexpressing U251 cell (NTN1FH)
and tagged NTN4-overexpressing U251 cell (NTN4FH) were used as controls. We used Q-RT-PCR to determine the expression levels of
NTN4 or NTN1 at the mRNA level in these cell lines. (C) The cells were lysed and subjected to immunoprecipitation with anti-FLAG agarose
and immunoblot analysis with ITGB4 antibody. Overexpression of native NTN1 did not competewith NTN4 for binding to ITGB4. Conversely,
overexpression of native NTN4 did not compete with NTN1 for binding to ITGB4. Immunoblot analysis with HA antibody was applied to
confirm the equal expression levels.
Figure W7. Functional relationships between NTN4 and NTN1 in the promotion of glioblastoma cell growth. (A) NTN1 was overexpressed
in U251MG cells (NTN1.pcDNA3). In addition, NTN4 expression was silenced by the short hairpin system in NTN1-overexpressing U251 cells.
(B) BrdU incorporation assay indicated that NTN1 overexpression did not alter cell growth. Furthermore, suppression of NTN4 in NTN1-
overexpressing cells or control cells decreased cell proliferation to the same extent comparedwith nontransfected cells (wt) or to nontargeting
control cells. (C) We knocked down NTN1 expression in U251MG cells. Q-RT-PCR was applied again to determine NTN1-silencing effects
at the mRNA level. (D) Decreased NTN1 expression in control U251MG cells resulted in the inhibition of cell proliferation, and NTN4 over-
expression did not neutralize this effect. (E) U251MG cells were stably transduced with the NTN4 gene, the NTN1 gene, or the empty vector
control, respectively, or in combination. BrdU incorporation assay was performed. Single or combined overexpression of NTN4 or NTN1 in
U251MG cells had no significant effects on cell proliferation comparedwith empty vector control. (F) U251MG cells were infected with scram-
bled control or NTN4/NTN1 shRNA separately or in combination. The expression levels were confirmed by Q-RT-PCR analysis at the mRNA
level. (G) Suppression of NTN1 inNTN4 silencedU251MGcellswas still able to reduce cell proliferation.Mean±SE, n≥ 3. **P< .01. *P< .05.
Figure W8. The expression of NTN4 during glioma progression and in glioblastoma cell lines. (A) Published microarray data from
www.oncomine.org revealed that glioma cells tend to decrease NTN4 expression after glioma progression. The log2 median of centered
intensities of NTN4 is 1.121 (normal tissue), 1.161 (grade 2 glioma), 0.535 (grade 3 glioma), −0.097 (grade 4 glioblastoma). (B) NTN4
expression in 20 glioblastoma cell lines versus normal brain tissue. The log2 median of centered intensities of NTN4 in 20 glioblastoma
cell lines is 2.242, whereas the value is −0.983 in normal brain tissue. This suggests that most glioblastoma cell lines express NTN4.
